Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Interest Expenses (2022 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Interest Expenses for 4 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • Quarterly Interest Expenses fell 15.27% to $4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.6 million through Dec 2025, up 2.67% year-over-year, with the annual reading at $20.6 million for FY2025, 0.1% changed from the prior year.
  • Interest Expenses for Q4 2025 was $4.6 million at Rhythm Pharmaceuticals, down from $4.7 million in the prior quarter.
  • The five-year high for Interest Expenses was $5.8 million in Q2 2025, with the low at $46000.0 in Q2 2022.
  • Average Interest Expenses over 4 years is $4.0 million, with a median of $4.6 million recorded in 2024.
  • The sharpest move saw Interest Expenses surged 7080.43% in 2023, then dropped 15.27% in 2025.
  • Over 4 years, Interest Expenses stood at $3.0 million in 2022, then skyrocketed by 51.11% to $4.6 million in 2023, then grew by 19.71% to $5.4 million in 2024, then dropped by 15.27% to $4.6 million in 2025.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $4.6 million, $4.7 million, and $5.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.